Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study.
Tokmakova MP, Skali H, Kenchaiah S, Braunwald E, Rouleau JL, Packer M, Chertow GM, Moyé LA, Pfeffer MA, Solomon SD. Tokmakova MP, et al. Among authors: kenchaiah s. Circulation. 2004 Dec 14;110(24):3667-73. doi: 10.1161/01.CIR.0000149806.01354.BF. Epub 2004 Nov 29. Circulation. 2004. PMID: 15569840 Clinical Trial.
Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
Kenchaiah S, Davis BR, Braunwald E, Rouleau JL, Dagenais GR, Sussex B, Steingart RM, Brown EJ Jr, Lamas GA, Gordon D, Bernstein V, Pfeffer MA; Survival and Ventricular Enlargement Trial. Kenchaiah S, et al. Am Heart J. 2004 Aug;148(2):356-64. doi: 10.1016/j.ahj.2004.02.011. Am Heart J. 2004. PMID: 15309009 Clinical Trial.
Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
Janardhanan R, Kenchaiah S, Velazquez EJ, Park Y, McMurray JJ, Weaver WD, Finn PV, White HD, Marin-Neto JA, O'Connor C, Pfeffer MA, Califf RM, Solomon SD; VALIANT Investigators. Janardhanan R, et al. Among authors: kenchaiah s. Am Heart J. 2006 Jul;152(1):183-9. doi: 10.1016/j.ahj.2005.11.013. Am Heart J. 2006. PMID: 16824854
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
Kenchaiah S, Pocock SJ, Wang D, Finn PV, Zornoff LA, Skali H, Pfeffer MA, Yusuf S, Swedberg K, Michelson EL, Granger CB, McMurray JJ, Solomon SD; CHARM Investigators. Kenchaiah S, et al. Circulation. 2007 Aug 7;116(6):627-36. doi: 10.1161/CIRCULATIONAHA.106.679779. Epub 2007 Jul 16. Circulation. 2007. PMID: 17638930 Clinical Trial.
Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).
Shamshad F, Kenchaiah S, Finn PV, Soler-Soler J, McMurray JJ, Velazquez EJ, Maggioni AP, Califf RM, Swedberg K, Kober L, Belenkov Y, Varshavsky S, Pfeffer MA, Solomon SD; VALsartan In Acute myocardial iNfarcTion (VALIANT) Trial Investigators. Shamshad F, et al. Among authors: kenchaiah s. Am Heart J. 2010 Jul;160(1):145-51. doi: 10.1016/j.ahj.2010.02.037. Am Heart J. 2010. PMID: 20598985 Clinical Trial.
Cardiac remodeling in systemic hypertension.
Kenchaiah S, Pfeffer MA. Kenchaiah S, et al. Med Clin North Am. 2004 Jan;88(1):115-30. doi: 10.1016/s0025-7125(03)00168-8. Med Clin North Am. 2004. PMID: 14871054 Review.
Long-term trends in the incidence of and survival with heart failure.
Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS. Levy D, et al. Among authors: kenchaiah s. N Engl J Med. 2002 Oct 31;347(18):1397-402. doi: 10.1056/NEJMoa020265. N Engl J Med. 2002. PMID: 12409541 Free article.
32 results